The agreement involves AXA China Region Insurance and AXA International Reinsurance (Shanghai), marking a significant step toward expanding access to innovative oncology solutions across Greater China.
BNCT is a cutting-edge precision treatment designed to destroy tumor cells while sparing surrounding healthy tissue. With the rising incidence of head and neck cancers in regions such as Hong Kong, the partnership aims to diversify available treatment options and improve clinical outcomes for patients with aggressive or recurrent cancers.
Janet Lee, Chief Life and Health Insurance Officer at AXA Hong Kong and Macau, emphasized the company’s ongoing commitment to integrating medical innovation into its insurance offerings.
“AXA remains deeply committed to a customer-first philosophy, offering comprehensive and high-quality medical protection tailored to individual needs,” Lee said. “We continuously track healthcare trends and integrate cutting-edge medical solutions into our insurance plans to ensure our services remain relevant and impactful. This collaboration with China Biotech Services reflects our ambition to enhance health protection through innovative technologies and broaden the range of care options available to our customers.”
The partnership underlines AXA’s strategic focus on combining insurance with emerging medical technologies to deliver better value and support for patients navigating complex health challenges.
